FBInvestor
Stocks / Moonlake Immunotherapeutics
Institutional Ownership

Moonlake Immunotherapeutics

CUSIP 61559X104CLASS A ORDMLTXQ1 2026

Earnings

Quarterly EPS and revenue are sourced from SEC XBRL financial statements. We ingest the top issuers first; this fills in as coverage expands (or this security isn't mapped to an SEC filer yet).

Coming soon